Sectors & Industries HealthcareDrug Manufacturers - General
Best General Drug Manufacturer Stocks to Buy Now (2026)
Top general drug manufacturer stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +28.50% per year, and are the best general drug manufacturer stocks to buy now. Learn More.

Industry: Drug Manufacturers - Gene...

Financials Momentum Sentiment Forecast Dividends Due Diligence

General Drug Manufacturers is Zen Rated A and is the 7th ranked industry out of 146 stock market industries

Ticker	Company	Market Cap	Revenue	EBITDA	Earnings	EPS	Rev. Y/Y	Rev. 5Y	Earn. Y/Y	Earn. 5Y	Earnings Date
BMY	BRISTOL MYERS SQUIBB CO	$115.79B	$48.48B	$13.19B	$7.28B	$3.57	1.78%	2.52%	33.21%	N/A	2026-07-30
LLY	ELI LILLY & CO	$1.13T	$72.25B	$33.17B	$25.28B	$28.19	47.44%	23.17%	128.44%	33.25%	2026-08-06
BIIB	BIOGEN INC	$30.78B	$9.94B	$2.43B	$1.37B	$9.35	1.23%	-4.64%	-7.97%	-13.53%	2026-07-29
SNY	SANOFI	$103.92B	$55.61B	$17.97B	$9.30B	$3.81	19.14%	3.82%	62.78%	-8.84%	2026-07-30
ABBV	ABBVIE INC	$450.11B	$62.82B	$16.65B	$3.64B	$2.03	9.50%	4.59%	-13.98%	-6.16%	2026-07-31
AMRN	AMARIN CORP PLC	$329.84M	$216.76M	-$27.75M	-$33.61M	-$1.60	1.24%	-18.46%	N/A	N/A	2026-07-29
GSK	GSK PLC	$106.79B	$44.30B	$9.81B	$7.88B	$3.91	6.74%	7.06%	92.03%	1.30%	2026-07-28
AZN	ASTRAZENECA PLC	$294.56B	$60.44B	$20.46B	$10.39B	$6.71	9.93%	16.99%	33.93%	17.16%	2026-07-27
AMGN	AMGEN INC	$197.77B	$37.22B	$16.67B	$7.80B	$14.48	9.07%	8.14%	31.04%	3.55%	2026-08-04
MRK	MERCK & CO INC	$313.12B	$65.77B	$19.40B	$8.94B	$3.57	2.89%	9.46%	-48.19%	5.13%	2026-08-04
PFE	PFIZER INC	$135.19B	$63.32B	$14.46B	$7.49B	$1.31	1.36%	6.56%	-5.76%	-7.26%	2026-08-04
GILD	GILEAD SCIENCES INC	$160.92B	$29.74B	$14.49B	$9.22B	$7.42	3.48%	3.07%	55.56%	97.01%	2026-08-06
GRFS	GRIFOLS SA	$4.93B	$8.75B	$1.85B	$467.44M	$0.69	17.83%	6.33%	189.17%	-8.77%	2026-07-27
JNJ	JOHNSON & JOHNSON	$624.26B	$96.36B	$33.71B	$21.04B	$8.73	7.87%	2.73%	-3.64%	8.75%	2026-07-15
NVS	NOVARTIS AG	$296.69B	$56.58B	$28.03B	$13.53B	$7.02	6.31%	2.55%	9.18%	14.87%	2026-07-16
SCLX	SCILEX HOLDING CO	$68.52M	$33.86M	-$359.15M	-$419.68M	-$40.47	-33.22%	N/A	N/A	N/A	2026-08-12
MIRA	MIRA PHARMACEUTICALS INC	$40.13M	$0.00	-$9.81M	-$31.37M	-$1.27	N/A	N/A	N/A	N/A	2026-08-13
MDCX	MEDICUS PHARMA LTD	$26.06M	$0.00	-$38.92M	-$51.22M	-$2.69	N/A	N/A	N/A	N/A	2026-08-10
OGN	ORGANON & CO	$3.56B	$6.16B	$1.39B	$246.00M	$0.94	-2.08%	-0.31%	-67.70%	-33.69%	2026-08-04
NSRX	NASUS PHARMA LTD	$30.97M	$0.00	-$5.92M	-$5.86M	-$0.72	N/A	N/A	N/A	N/A

General Drug Manufacturer Stocks FAQ

What are the best general drug manufacturer stocks to buy right now in Jul 2026?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best general drug manufacturer stocks to buy right now are:

1. Bristol Myers Squibb Co (NYSE:BMY)

Bristol Myers Squibb Co (NYSE:BMY) is the #1 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Bristol Myers Squibb Co (NYSE:BMY) is: Value: A, Growth: C, Momentum: C, Sentiment: B, Safety: B, Financials: B, and AI: B.

Bristol Myers Squibb Co (NYSE:BMY) has a Due Diligence Score of 52, which is 16 points higher than the general drug manufacturer industry average of 36.

BMY passed 18 out of 38 due diligence checks and has strong fundamentals. Bristol Myers Squibb Co has seen its stock return 21.96% over the past year, underperforming other general drug manufacturer stocks by -20 percentage points.

Bristol Myers Squibb Co has an average 1 year price target of $64.00, an upside of 12.87% from Bristol Myers Squibb Co's current stock price of $56.70.

Bristol Myers Squibb Co stock has a consensus Buy recommendation according to Wall Street analysts. Of the 13 analysts covering Bristol Myers Squibb Co, 38.46% have issued a Strong Buy rating, 7.69% have issued a Buy, 53.85% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Eli Lilly & Co (NYSE:LLY)

Eli Lilly & Co (NYSE:LLY) is the #2 top general drug manufacturer stock out of 20 with a Zen Rating of B. Stocks with a rating of B have had an average return of +17.17% per year. Learn more.

The Component Grade breakdown for Eli Lilly & Co (NYSE:LLY) is: Value: B, Growth: C, Momentum: B, Sentiment: C, Safety: C, Financials: B, and AI: B.

Eli Lilly & Co (NYSE:LLY) has a Due Diligence Score of 62, which is 26 points higher than the general drug manufacturer industry average of 36.

LLY passed 25 out of 38 due diligence checks and has strong fundamentals. Eli Lilly & Co has seen its stock return 55.27% over the past year, overperforming other general drug manufacturer stocks by 14 percentage points.

Eli Lilly & Co has an average 1 year price target of $1,255.53, an upside of 4.62% from Eli Lilly & Co's current stock price of $1,200.06.

Eli Lilly & Co stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 15 analysts covering Eli Lilly & Co, 73.33% have issued a Strong Buy rating, 20% have issued a Buy, 0% have issued a hold, while 6.67% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Biogen (NASDAQ:BIIB)

Biogen (NASDAQ:BIIB) is the #3 top general drug manufacturer stock out of 20 with a Zen Rating of B. Stocks with a rating of B have had an average return of +17.17% per year. Learn more.

The Component Grade breakdown for Biogen (NASDAQ:BIIB) is: Value: A, Growth: C, Momentum: B, Sentiment: C, Safety: B, Financials: B, and AI: C.

Biogen (NASDAQ:BIIB) has a Due Diligence Score of 46, which is 10 points higher than the general drug manufacturer industry average of 36.

BIIB passed 14 out of 33 due diligence checks and has strong fundamentals. Biogen has seen its stock return 60.19% over the past year, overperforming other general drug manufacturer stocks by 19 percentage points.

Biogen has an average 1 year price target of $219.00, an upside of 5.06% from Biogen's current stock price of $208.46.

Biogen stock has a consensus Buy recommendation according to Wall Street analysts. Of the 19 analysts covering Biogen, 31.58% have issued a Strong Buy rating, 26.32% have issued a Buy, 36.84% have issued a hold, while 5.26% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the general drug manufacturer stocks with highest dividends?

Out of 14 general drug manufacturer stocks that have issued dividends in the past year, the 3 general drug manufacturer stocks with the highest dividend yields are:

1. Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) has an annual dividend yield of 5.44%, which is 3 percentage points higher than the general drug manufacturer industry average of 2.84%. Pfizer's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Pfizer's dividend has shown consistent growth over the last 10 years.

Pfizer's dividend payout ratio of 131.3% indicates that its high dividend yield might not be sustainable for the long-term.

2. Bristol Myers Squibb Co (NYSE:BMY)

Bristol Myers Squibb Co (NYSE:BMY) has an annual dividend yield of 4.43%, which is 2 percentage points higher than the general drug manufacturer industry average of 2.84%. Bristol Myers Squibb Co's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Bristol Myers Squibb Co's dividend has shown consistent growth over the last 10 years.

Bristol Myers Squibb Co's dividend payout ratio of 70% indicates that its high dividend yield is sustainable for the long-term.

3. Sanofi (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) has an annual dividend yield of 4.15%, which is 1 percentage points higher than the general drug manufacturer industry average of 2.84%. Sanofi's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Sanofi's dividend has shown consistent growth over the last 10 years.

Sanofi's dividend payout ratio of 58.1% indicates that its high dividend yield is sustainable for the long-term.

Why are general drug manufacturer stocks down?

General drug manufacturer stocks were down -1.78% in the last day, and down -1.15% over the last week. Novartis Ag was the among the top losers in the drug manufacturers - general industry, dropping -2.76% yesterday.

Novartis shares are trading lower as investors await the FDA's decision on Vera Therapeutics' rare kidney disease drug, which will compete with the company's IgAN drug. The company announced it will acquire Myricx Bio.

What are the most undervalued general drug manufacturer stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued general drug manufacturer stocks right now are:

1. Biogen (NASDAQ:BIIB)

Biogen (NASDAQ:BIIB) is the most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Biogen has a valuation score of 71, which is 42 points higher than the general drug manufacturer industry average of 29. It passed 5 out of 7 valuation due diligence checks.

Biogen's stock has gained 60.19% in the past year. It has overperformed other stocks in the general drug manufacturer industry by 19 percentage points.

2. Bristol Myers Squibb Co (NYSE:BMY)

Bristol Myers Squibb Co (NYSE:BMY) is the second most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Bristol Myers Squibb Co has a valuation score of 43, which is 14 points higher than the general drug manufacturer industry average of 29. It passed 3 out of 7 valuation due diligence checks.

Bristol Myers Squibb Co's stock has gained 21.96% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -20 percentage points.

3. Gsk (NYSE:GSK)

Gsk (NYSE:GSK) is the third most undervalued general drug manufacturer stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Gsk has a valuation score of 29, which is 0 points higher than the general drug manufacturer industry average of 29. It passed 2 out of 7 valuation due diligence checks.

Gsk's stock has gained 39.02% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -3 percentage points.

Are general drug manufacturer stocks a good buy now?

53.85% of general drug manufacturer stocks rated by analysts are a buy right now. On average, analysts expect general drug manufacturer stocks to rise by 5.17% over the next year.

6.25% of general drug manufacturer stocks have a Zen Rating of A (Strong Buy), 43.75% of general drug manufacturer stocks are rated B (Buy), 43.75% are rated C (Hold), 6.25% are rated D (Sell), and 0% are rated F (Strong Sell).

What is the average p/e ratio of the drug manufacturers - general industry?

The average P/E ratio of the drug manufacturers - general industry is 41.49x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.

General Drug Manufacturer Stocks FAQ

1. Bristol Myers Squibb Co (NYSE:BMY)

2. Eli Lilly & Co (NYSE:LLY)

3. Biogen (NASDAQ:BIIB)

1. Pfizer (NYSE:PFE)

2. Bristol Myers Squibb Co (NYSE:BMY)

3. Sanofi (NASDAQ:SNY)

1. Biogen (NASDAQ:BIIB)

2. Bristol Myers Squibb Co (NYSE:BMY)

3. Gsk (NYSE:GSK)

Company

Stock Tools

Stock Ideas